Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_assertion type Assertion NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_head.
- NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_assertion description "[Prostate cancers respond to treatments that suppress androgen receptor (AR) function, with bicalutamide, flutamide, and cyproterone acetate (CPA) being AR antagonists in clinical use.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_provenance.
- NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_assertion evidence source_evidence_literature NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_provenance.
- NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_assertion SIO_000772 15256534 NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_provenance.
- NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_assertion wasDerivedFrom befree-20140225 NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_provenance.
- NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_assertion wasGeneratedBy ECO_0000203 NP650433.RAstikQvIptwftAjYzUIgV9t0TNhvB0nn8hPpFWkXaym4130_provenance.